Drug Interaction Report

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Coadministration with potent inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of topical sofpironium, which has been shown to be partially metabolized by the isoenzyme. In a pharmacokinetic study in patients with primary axillary hyperhidrosis, sofpironium systemic exposure (AUC) and peak plasma concentration (Cmax) increased approximately 2 -fold following concomitant use with the potent CYP450 2D6 inhibitor paroxetine at a 20 mg oral dose.

MANAGEMENT: Coadministration of topical sofpironium with potent CYP450 2D6 inhibitors should generally be avoided. If coadministration is required, monitor for sofpironium-related adverse effects which include blurred vision, urinary retention, difficulty controlling body temperature in warm environments, and dry mouth.

Alcohol can increase the nervous system side effects of FLUoxetine such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. You should avoid or limit the use of alcohol while being treated with FLUoxetine. Do not use more than the recommended dose of FLUoxetine, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. Talk to your doctor or pharmacist if you have any questions or concerns.